Your session is about to expire
← Back to Search
Nivolumab for Cancer
Study Summary
This trial is testing nivolumab as a treatment for cancer and autoimmune disorders. It will study the side effects of the drug and how well it works.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this endeavor currently have the capacity to enroll participants?
"Indeed, according to clinicaltrials.gov the current phase of this trial is participant recruitment which launched on April 4th 2019 and was most recently updated November 11th 2022. 300 individuals are needed from 42 different medical sites."
What is the aggregate number of people participating in this research?
"This clinical study necessitates 300 participants that meet the pre-defined conditions for enrollment. Patients will be able to join the trial at University of Kansas Health System Saint Francis Campus in Topeka, Connecticut and Yale University in New Haven, Illinois amongst other sites."
Is this endeavor an unprecedented medical investigation?
"Presently, there are 717 active trials of Nivolumab occurring in 49 countries and 2356 cities. This drug was first tested back in 2012 by Ono Pharmaceutical Co Ltd., with a total of 659 participants completing the Phase 1 & 2 stages. Since then, 259 studies have concluded their research."
What evidence exists regarding the use of Nivolumab in prior medical tests?
"Currently, Nivolumab is being studied in a total of 717 clinical trials. Out of these experiments, 82 are at the Phase 3 stage and 40281 medical sites have been selected as venues for this research. The majority of studies are based out Basel BE."
How many centers are administering this investigation?
"The trial is currently underway at 42 medical centres located in cities such as Topeka, New Haven and Kansas City. To limit any potential travel burden incurred by participants, it's crucial to select the nearest clinic when enrolling in this study."
Is there evidence that Nivolumab can be taken without causing detrimental effects?
"The clinical data available on Nivolumab's safety and efficacy is limited, resulting in a score of 1."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 1 Day
Most responsive sites:
- Huntsman Cancer Institute/University of Utah: < 24 hours
Share this study with friends
Copy Link
Messenger